Kolexia
Bazire Louis-Arnaud Oncologie radiothérapie
Bazire Louis-Arnaud
Oncologie radiothérapie
Ctre De Cancerologie De Charlebourg
La Garenne-Colombes, France
60 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs du sein triple-négatives Carcinomes Tumeurs de l'anus Carcinome épidermoïde Récidive tumorale locale Carcinome canalaire du sein Fractures de fatigue Radiodermite

Collaborateurs

Voir plus
Kirov Youlia
Kirov Youlia
Clcc Institut Curie, Paris, France
Fourquet Alain
Fourquet Alain
Clcc Institut Curie, Paris, France
Vincent-Salomon Anne
Vincent-Salomon Anne
Clcc Institut Curie, Paris, France
Pierga Jean-Yves
Pierga Jean-Yves
Clcc Institut Curie, Paris, France

Industries

Voir plus
MSD
6 collaboration(s)
Dernière en 2023
Ipsen
4 collaboration(s)
Dernière en 2023
Janssen
4 collaboration(s)
Dernière en 2022
B3TSI
2 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
RadioPARP: A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease
Essai Clinique (AstraZeneca)   29 janvier 2024
Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial.
Nature communications   22 juin 2023
Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.
JAMA oncology   19 décembre 2022
Concurrent Olaparib with Radiotherapy in Patients with Triple Negative Breast Cancer: Final Results of the RADIOPARP Phase 1 Trial
ASTRO Annual 2022 Meeting   01 novembre 2022
Safety and tolerability of olaparib combined with breast radiotherapy in patients with triple-negative breast cancer: Final results of the RADIOPARP phase 1 trial.
2022 ASCO Annual Meeting I   02 juin 2022
Combination of nivolumab with chemoradiotherapy for locally advanced cervical cancer: NiCOL phase I trial.
2022 ASCO Annual Meeting I   02 juin 2022
One-Year Toxicity Report of the RADIOPARP Phase I Trial Evaluating Olaparib With Radiotherapy for Triple Negative Breast Cancer
2021 Proceedings of the ASTRO 63rd Annual Meeting   01 novembre 2021
What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   16 avril 2021
MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma.
Cancers   07 janvier 2021
Radioparp: A phase I of olaparib with radiation therapy (RT) in patients with inflammatory, locoregionally advanced or metastatic triple-negative breast cancer (TNBC) or patient with operated TNBC with residual disease—Preliminary results.
2020 ASCO Annual Meeting I   25 mai 2020